Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102â€™s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
16/07/26	CAD 0.5300	0.00%	500
15/07/26	CAD 0.5300	-7.02%	5,500
14/07/26	CAD 0.5700	+1.79%	500

Delayed Quote Toronto S.E.

More quotes

Income Statement and Estimates

More financial data

Net sales - Rate of surprise

Company calendar

Delayed Toronto S.E. Other stock markets 05:43:47 17/07/26 am AEST			5-day change	1st Jan Change
0.5300 ^CAD	0.00%		-7.02%	-18.46%

14/07	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome	CI
14/07	Thiogenesis Therapeutics' Treatment For Leigh Syndrome Receives FDA Rare Pediatric Disease Designation	MT

Market Cap	27.47M 19.61M 17.14M 15.81M 14.58M 1.89B 28.08M 189M 74.34M 925M 73.64M 72.03M 3.18B	P/E 2024	-8.65x	P/E 2025	-4.25x
Enterprise Value	25.86M 18.46M 16.13M 14.88M 13.72M 1.78B 26.43M 178M 69.97M 870M 69.31M 67.79M 3B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	87.27%	Yield 2024 *	-	Yield 2025	-

14/07	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome	CI
14/07	Thiogenesis Therapeutics' Treatment For Leigh Syndrome Receives FDA Rare Pediatric Disease Designation	MT
18/06	Thiogenesis Therapeutics Appoints Gilad Aharon to its Board	MT
17/06	Thiogenesis Therapeutics, Corp. Appoints Gilad Aharon to Its Board of Directors	CI
04/06	Thiogenesis Therapeutics, Corp. announced that it has received CAD 9.07185 million in funding	CI
26/05	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
12/05	Thiogenesis Therapeutics to Raise $8 Million Via a Non-Brokered Private Placement	MT
12/05	Thiogenesis Therapeutics, Corp. announced that it expects to receive CAD 8 million in funding	CI
01/05	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/04	Thiogenesis Therapeutics, Corp. Auditor Raises 'Going Concern' Doubt	CI
03/02	Thiogenesis Therapeutics, Corp. Provides Program Update	CI
24/01	Thiogenesis Therapeutics, Corp. Announces the Presentation of Interim Data from Its Phase 2 (Eu) Clinical Study of Tti-0102 in Patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes At Mitocon 2026	CI
27/11	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

13/07	Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome	NE
17/06	Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors	NE
03/06	Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million	NE
02/06	Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares	NE
11/05	Thiogenesis Announces Non-Brokered Private Placement	NE

Thiogenesis Therapeutics, Corp. Stock

Stocks

TTI

CA88410L1022

Biotechnology & Medical Research

Valuation: Thiogenesis Therapeutics, Corp.

Chart: Thiogenesis Therapeutics, Corp.

Latest news : Thiogenesis Therapeutics, Corp.

Analysts' recommendations: Thiogenesis Therapeutics, Corp.

Press Releases: Thiogenesis Therapeutics, Corp.

Quotes and Performance

Course Extremes

Managers and Directors: Thiogenesis Therapeutics, Corp.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Net sales - Rate of surprise

1 week	-7.02%
Current month	-1.85%
1 month	-7.02%
3 months	-13.11%
6 months	-18.46%
Current year	-18.46%

1 week	0.53	0.57
1 month	0.53	0.57
Current year	0.44	0.66
1 year	0.44	0.87
3 years	0.44	1.06
5 years	0.38	1.06
10 years	0.38	1.06

Manager	Title	Age	Since
Patrice Rioux CEO	Chief Executive Officer	75	31/03/2022
Brook Riggins CEO	Chief Executive Officer	60	-

Director	Title	Age	Since
Christopher Starr CHM	Chairman	73	31/03/2022
Patrice Rioux BRD	Director/Board Member	75	31/03/2022
Brook Riggins BRD	Director/Board Member	60	03/05/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/6/26	W. Mullally	Sell	Director	150,000	0.2894%
11/9/25	W. Mullally	Option	Director	75,000	0.1702%
1/8/25	W. Mullally	Sell	Director	64,000	0.1453%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THIOGENESIS THERAPEUTICS, CORP.	0.00%	-7.02%	-33.75%	-19.70%	19.57M
LONZA GROUP AG	-1.29%	-3.11%	-0.39%	+4.92%	49.7B
REVOLUTION MEDICINES, INC.	+3.13%	-1.40%	+371.87%	+592.47%	38.09B
BEONE MEDICINES AG	-1.64%	+4.38%	+7.38%	+57.54%	35.29B
IQVIA HOLDINGS INC.	-1.81%	-0.61%	+26.54%	-6.68%	35.13B
CELLTRION, INC.	+0.06%	+1.56%	+4.41%	+27.42%	27.22B
ASCENDIS PHARMA A/S	+1.48%	-2.56%	-	-	16.14B
MEDPACE HOLDINGS, INC.	+0.07%	-0.01%	+68.62%	+117.57%	15.36B
EUROFINS SCIENTIFIC SE	+1.12%	+1.91%	+15.90%	+19.65%	13.89B
ICON PUBLIC LIMITED COMPANY	+1.20%	+1.96%	+16.42%	-30.22%	13.02B
Average	+0.20%	-0.51%	+53.00%	+84.77%	24.39B
Weighted average by Cap.	-0.10%	-0.64%	+74.42%	+118.74%

	2024	2025
Net sales	-	-
Net income	-3.15M -2.25M -1.96M -1.81M -1.67M -216M -3.22M -21.64M -8.51M -106M -8.43M -8.25M -365M	-7.43M -5.3M -4.63M -4.27M -3.94M -510M -7.59M -51.09M -20.09M -250M -19.91M -19.47M -861M
Net Debt	-3.85M -2.75M -2.4M -2.21M -2.04M -264M -3.93M -26.47M -10.41M -130M -10.31M -10.09M -446M	-1.62M -1.15M -1.01M -930K -857K -111M -1.65M -11.12M -4.37M -54.4M -4.33M -4.24M -187M